MeCure earns N20.15b
MeCure Industries made N20.15 billion in the first quarter, representing a 52 per cent year-on-year growth, with PBT of N1.92 billion, up 136 per cent year-on-year, and Earnings Per Share
MeCure Industries made N20.15 billion in the first quarter, representing a 52 per cent year-on-year growth, with PBT of N1.92 billion, up 136 per cent year-on-year, and Earnings Per Share of N0.34, a 143 per cent year-on-year increase.
Co-Chief Executive Officer, Mrs Dukor Ndidi, announced this in a statement.
As at September 2024, its profit was N1.5 billion. In December, revenue rose to N77.69 billion, a 69 per cent rise. Profit was N6.46 billion. While its EPS in 2024 was N0.58, its growth was 177 per cent and gearing rate 70 per cent.
She said: ‘’MeCure’s Q1 performance reflects strength of its strategic positioning. It benefits from investment in local manufacturing capacity, which reduces exposure to foreign exchange risks and supports cost efficiency.’’
Read Also: Xenophobia: Tinubu orders tight monitoring as anti-foreigner protests loom in South Africa
‘‘Enhanced supply chain diversification and improved procurement strategies have also helped mitigate input cost volatility and ensure product availability across key markets.
‘’Despite ongoing cost pressures—particularly from elevated borrowing costs in a high-interest-rate environment and inflation-driven increases in operating expenses—the company maintained strong profitability growth. This was supported by disciplined cost management, improved product mix, and continued focus on high-margin therapeutic segments.The significant growth in PBT and EPS underscores improved operational efficiency and the company’s ability to translate top-line growth into enhanced shareholder value.
‘’Also, supportive government policies, including continued incentives for local pharmaceutical manufacturing, have helped cushion the impact of imported input costs and reinforced the company’s long-term strategy of deepening local production.’’
Looking ahead, ‘’MeCure remains focused on sustaining growth momentum through capacity expansion,innovation,and broader market penetration.While macroeconomic uncertainties persist— domestically and globally—the company is well-positioned to capitalise on emerging opportunities in the country’s healthcare sector and continue delivering value to stakeholders,’’ she added.
